von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease

42 subjects (33 adults and 9 children) with von Willebrand disease (VWD) undergoing elective surgery.

von Willebrand factor/factor VIII (VWF/FVIII) concentrate (Humate-P), with dosing based on VWF:RCo and FVIII pharmacokinetic assessments before surgery (median loading doses 42.6 to 61.2 IU VWF:RCo kg-1, median 10 doses per subject).

Haemostatic efficacy assessed on a 4-point scale (excellent, good, moderate/poor or none), safety, and optimal dosing.